Effect of Melagatran on Prothrombin Time Assays Depends on the Sensitivity of the Thromboplastin and the Final Dilution of the Plasma Sample

Christer Mattsson; Angela Menschiek-Lundin; Karin Wåhlander; Tomas L. Lindahl

doi:10.1055/s-0037-1616094

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 86(02): 611-615
DOI: 10.1055/s-0037-1616094

Review Article

Schattauer GmbH

Effect of Melagatran on Prothrombin Time Assays Depends on the Sensitivity of the Thromboplastin and the Final Dilution of the Plasma Sample

Christer Mattsson

¹Department of Cell Biology and Biochemistry, AstraZeneca R&D, Mölndal, Sweden

,

Angela Menschiek-Lundin

¹Department of Cell Biology and Biochemistry, AstraZeneca R&D, Mölndal, Sweden

,

Karin Wåhlander

¹Department of Cell Biology and Biochemistry, AstraZeneca R&D, Mölndal, Sweden

³Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Göteborg, Sweden

,

Tomas L. Lindahl

²Department of Clinical Chemistry, University Hospital, Linköping, Sweden

› Author Affiliations

Abstract

Summary

Prothrombin time (PT) assays are clotting methods that measure the activity of vitamin K-dependent coagulation factors (F) II, VII, and X. There are three main types of PT assays in general usage, namely the Quick assay, Owren’s assay and PT dry chemistry test cards. PT assays were initially developed to monitor dose-adjustments of vitamin K antagonists such as warfarin. The aim of the present study was to investigate whether commercially available PT assays are suitable for evaluating the anticoagulant activity of direct thrombin inhibitors. Melagatran, a reversible direct thrombin inhibitor, was added to human plasma at concentrations ranging from 0.1 to 2.0 μmol/l. Seventeen different commercially available PT kits were used, including thirteen Quick reagents, two Owren reagents and two PT test cards. The sensitivity of the different reagents, expressed as the concentration of melagatran that doubled the prothrombin time (IC₅₀) varied widely, with Thromboplastin S and Thromboplastin HS being the most sensitive (IC₅₀ = 0.9 μmol/l). The reagents with apparently the lowest sensitivity were the two Owren reagents Nycotest PT and SPA 50 with an IC₅₀ of 2.2 and 2.9 μmol/L, respectively. This is most likely due to a higher dilution of melagatran in these assays compared to the dilution in the Quick assays. The results were also dependent on the International Sensitivity Index (ISI) of each reagent. The concentration of melagatran that produced an International Normalized Ratio (INR) of 2 was calculated from dose-response curves for each assay, and these results revealed that reagents with a high ISI value gave an INR of 2 at much lower concentrations of melagatran (0.5-0.7 μmol/L) than those with an ISI-values around one (0.9-1.2 μmol/L). It was found that INR depends not only on the plasma concentration of melagatran, but also on the sensitivity of the PT reagent and on the final dilution of the plasma sample in the prothrombin time assay. Thus, since the same melagatran concentration can be associated with widely varying PT/INR results depending on the specific assay used it is concluded that PT assays and INR can not be used to monitor melagatran activity.

Keywords

Prothrombin time - melagatran - direct thrombin inhibitors - anticoagulants - thromboplastin

Full Text

References

References
1 Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 510-1.
2 Aggeler PM, Lucia SP. Study of some variables affecting the prothrombin time. Proc Soc Exp Biol Med 1938; 38: 11-6.
3 Aggeler PM, Howard J, Lucia S, Clark W, Astaff A. Standardization of the Quick prothrombin test. Blood 1946; 1: 220-33.
4 Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-8.
5 Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959; 2: 754-8.
6 Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Ekg M, Mattsson C, Deinum J, Persson S, Larlsson O, Nilsson A, Sörensen H. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8.
7 Beguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refutations on the mode of action of heparins. Haemostasis 1999; 29: 170-8.
8 Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Johnsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsen M. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999; 81: 358-63.
9 Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97.
10 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin and by gel filtration. Thromb Res 1976; 9: 575-83.